A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

India-based Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

The latest candidate to move into phase 2 is NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is the most advanced candidate in a $2.6 billion alliance with Neurocrine signed ...

TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).